SCHEMBL1360126

SCHEMBL1360126

COc1ccccc1OCCCc1oc(SCCCO)nc1-c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DHPS P49366 1/20 0.41
ALDH1A1 P00352 2/20 0.38
HSD17B10 Q99714 2/20 0.38
THRB P10828 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 5/20 0.35
MAPK1 P28482 4/20 0.35
TSHR P16473 3/20 0.35
GAA P10253 2/20 0.35
HPGD P15428 2/20 0.35
TP53 P04637 1/20 0.35
ALOX15 P16050 1/20 0.35
LMNA P02545 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1361665 0.82 GCGR (0.38) DHPSALDH1A1HSD17B10THRBSMN1; SMN2
SCHEMBL1361698 0.81 MAPT (0.41) DHPSALDH1A1HSD17B10THRBSMN1; SMN2
SCHEMBL1362462 0.81 L3MBTL1 (0.38) DHPSALDH1A1HSD17B10THRBSMN1; SMN2
SCHEMBL1362813 0.79 DHPS (0.41) DHPSALDH1A1HSD17B10THRBSMN1; SMN2
SCHEMBL1361414 0.78 TSHR (0.38) DHPSALDH1A1HSD17B10THRBMAPT
SCHEMBL1363172 0.73 MAOB (0.40) DHPSALDH1A1HSD17B10THRBMAPT
SCHEMBL1361683 0.73 SLC2A1 (0.44) ALDH1A1HSD17B10SMN1; SMN2MAPTTSHR
SCHEMBL1361404 0.73 L3MBTL1 (0.36) DHPSALDH1A1HSD17B10THRBMAPT
SCHEMBL1362126 0.72 MAPT (0.46) ALDH1A1THRBSMN1; SMN2MAPTTSHR
SCHEMBL962882 0.72 MAPT (0.36) DHPSALDH1A1HSD17B10THRBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067453-B2 Oxazole compound to treat or prevent diabetic neuropathy; 4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl-2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-29 US disclosed
US-20080269219-A1 Neurotrophin production/secretion promoting agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-7396848-B1 oxazole derivatives to treat diabetic neuropathy and/or other kinds of peripheral neuropathy; 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-08 US disclosed
EP-1206472-B1 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-10-01 EP disclosed
US-6605629-B1 Oxazole derivatives; low toxicity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-08-12 US disclosed
EP-1206472-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT Takeda Chemical Industries, Ltd. (JP) 2002-05-22 EP disclosed
WO-2001014372-A2 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269219-A1 Neurotrophin production/secretion promoting agent BDNF, NGF, NTRK2 DHPS 2390/4885ALDH1A1 937/4885HSD17B10 608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.